Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ebola vaccine immunity under the microscope: how long does protection last?

NCT ID NCT05313139

Knowledge-focused Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how long the Ebola vaccine (rVSV-ZEBOV) protects health workers in the Democratic Republic of the Congo. Researchers measured immune cells and antibodies in 133 vaccinated health workers to see if protection lasts beyond 1-2 years. The goal is to understand if booster shots are needed, especially after recent Ebola cases in previously vaccinated people.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rVSV-ZEBOV vaccine
What this could lead to
If successful, this could show how long the Ebola vaccine protects health workers and whether booster doses are needed.
What could go wrong
This is an observational study, not a treatment trial. It only measures immune responses and cannot prove the vaccine prevents future infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

133 people

The number who actually took part.

Started

Dec 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Health care workers from Institut National de Recherche Biomédicale (INRB) Kinshasa and Institut National de Recherche Biomédicale (INRB) Goma, who previously or recently received (primary and booster dose), or did not receive (cf. controls) the rVSV-ZEBOV vaccine.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is willing and able to give informed consent for participation in the study * Subject can be contacted by phone, email or physical address * Subject is aged 18 years or above * Subject must have a ID card (or other identification document) For vaccinated group: \- Subject must be receiving the rVSV-ZEBOV vaccine (first or second dose) at time of inclusion OR has received a first rVSV-ZEBOV vaccine dose prior to inclusion of which vaccination date and brand is known For unvaccinated group (controls): Subject must NOT have received the rVSV-ZEBOV vaccine nor had any prior close contact with EBOV patients Exclusion Criteria: * Subject was previously diagnosed with EVD * Subject has any contraindication to venipuncture, as determined by clinical judgement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune response

Contacts and locations

Locations

  • Institut National de Recherche Biomédicale (INRB)

    Goma, Democratic Republic of the Congo

  • Institut National de Recherche Biomédicale (INRB)

    Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.